企業概要
Big Tree Cloud Holdings Limited is an entity primarily engaged in the manufacturing and distribution of personal care products alongside various consumer goods. The company operates within the Consumer Defensive sector, specifically targeting the Household & Personal Products industry, which typically offers stability through essential consumption needs regardless of economic cycles. This market participant maintains a relatively modest scale with a total market capitalization of $12.50M and an annual revenue (TTM) of $7.32M, supported by a workforce of 50 employees. The valuation figures indicate that the company operates as a micro-cap entity with limited resources, suggesting a niche position where revenue generation is constrained by the small number of personnel and the specialized nature of its product lines such as sanitary napkins and panty liners under the BIGTREE CLOUD and YALUOTA brand names.
財務健全性
The company reported a revenue (TTM) of $7.32M and achieved a net income (TTM) of $640,485, resulting in an EBITDA of $910,187. The significant gap between the $7.32M in revenue and the $640,485 in net income highlights a highly efficient cost structure where operating expenses are kept low relative to sales, although the negative operating margin complicates this specific interpretation. The firm generated a free cash flow of $1.99M, which demonstrates strong operational liquidity and provides the financial flexibility to fund operations or manage working capital without immediate reliance on external financing. Analysis of the three key margins reveals a gross margin of 66.9%, indicating high pricing power or low cost of goods sold for its sanitary products and OEM services, contrasted sharply by an operating margin of -15.3% and a profit margin of 8.7% that reflects the volatility in overhead costs or specific accounting adjustments. Despite holding cash assets of $859,848, the company carries a debt load of $1.90M, resulting in a negative price-to-book ratio of -1.64 and a debt-to-equity metric that is not available due to the negative book value, suggesting a balance sheet that is currently leveraged in a manner that depresses shareholder equity. Furthermore, the current ratio stands at 0.28, which signals potential short-term liquidity constraints as current assets are insufficient to cover current liabilities without liquidating assets or raising new capital. Return on Equity is not available, while the Return on Assets sits at -0.2%, revealing that management effectiveness in generating profit from the asset base has been challenged in the most recent reporting period.
バリュエーション評価
The trailing twelve-month P/E ratio is not available, as is the forward P/E, which implies that traditional earnings-based valuation multiples cannot be applied given the negative or negligible book value context. The price-to-book ratio is recorded at -1.64, a figure that indicates the market is valuing the company based on earnings potential rather than tangible book value, as a negative multiple suggests the market cap exceeds the negative equity or that the book value is negligible. Alternative valuation metrics provide further insight, with a price-to-sales ratio of 1.71 and an EV/EBITDA of 166.08, suggesting the stock is priced at a premium relative to its sales volume but also indicating that the enterprise value is extremely high relative to earnings before interest, taxes, depreciation, and amortization due to the low EBITDA denominator. The stock has experienced significant volatility, trading between a 52-week high of $146.60 and a 52-week low of $2.18, placing the current trading price well below the recent peak and reflecting the extreme price range characteristic of small-cap biotechnology or speculative consumer stocks. With a beta of 1.51, the stock exhibits price volatility that is substantially higher than the broader market, moving 51% more than the market average in response to systemic risk factors.
Growth & Income
Revenue growth (YoY) has declined by 17.3%, while earnings growth (YoY) surged by 212.0%, indicating that earnings are expanding at a rate far faster than revenue, which often occurs when a company benefits from one-time cost reductions or non-recurring income items rather than top-line expansion. The company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning all available earnings are retained within the business to fund operations, research, or reinvestment into growth initiatives rather than being distributed to shareholders. Consequently, the overall growth and income profile is defined by aggressive reinvestment strategies and earnings expansion despite shrinking revenue, rather than a steady stream of dividend income for passive investors. This structure prioritizes capital appreciation potential over current income generation, aligning with the company's status as a small-cap entity seeking to grow its market share in the personal care sector.